- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Penn Medicine | Strategic Alliance Partners
.png?fit=crop&auto=format)
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer.
Collaboration is, and always has been, a cornerstone of Penn Medicine’s approach to groundbreaking research and quality care. Penn Medicine’s comprehensive cancer system includes the Abramson Cancer Center and Roberts Proton Therapy Center in Philadelphia, the Ann B. Barshinger Cancer Institute, Penn Medicine Princeton Cancer Center, and proton therapy center in Lancaster, the Penn Medicine | Virtua Health Proton Therapy Center in South New Jersy, and dozens of outpatient multispecialty care locations that stretch from the Susquehanna River in Pennsylvania to the New Jersey shore.
The Abramson Cancer Center has proudly been NCI-Designated Comprehensive since 1973. The Abramson Cancer Center is one of a select group of cancer centers in the country awarded the prestigious designation of Comprehensive Cancer Center by the National Cancer Institute. This status, which has been awarded to the Abramson Cancer Center continuously for the past 47 years, reflects our outstanding research, clinical services, education and information services and community outreach.
Connect with us:
Latest from Penn Medicine
The Role of Biomarker Testing in Metastatic and Resectable NSCLC
November 08, 2024
Video
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council
November 06, 2024
Article
Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.
Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma
September 11, 2024
Video
Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.
Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma
August 31, 2024
Article
Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.
Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers
August 20, 2024
Article
Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.
Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males
August 12, 2024
Article
Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.
Dr Aggarwal on the Rationale For Evaluating CAN-2409 in NSCLC
August 12, 2024
Video
Charu Aggarwal, MD, MPH, FASCO, discusses the evaluation of CAN-2409, valacyclovir, and continued immune checkpoint inhibitors in NSCLC.
HyBryte Continues to Improve mCAILS in Early Cutaneous T-Cell Lymphoma
July 10, 2024
Article
Up to 12 months of treatment with SGX301 produced lesion responses in patients with early-stage cutaneous T-cell lymphoma.
Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma
June 18, 2024
Video
Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.
Dr Porter on Community-Based CAR T-Cell Therapy Administration for R/R CLL
June 12, 2024
Video
David L. Porter, MD, discusses the utility of CAR T-cell therapy in the community setting for relapsed/refractory chronic lymphocytic leukemia.
Dr Svoboda on the Efficacy of Armored huCART19-IL18 in R/R Lymphoma
June 10, 2024
Video
Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.
Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer
June 04, 2024
Video
Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.
Dr Porter on the Future of CAR T-Cell Therapy in Relapsed/Refractory CLL
May 30, 2024
Video
David L. Porter, MD, discusses the future of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
CAR T-Cell Therapy Makes its Mark in CLL
May 26, 2024
Article
David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.
Dr Porter on Understanding Gaps in CAR T-Cell Therapy for R/R CLL
May 24, 2024
Video
David L. Porter, MD, discusses knowledge gaps regarding the optimal use of CAR T-cell therapy in relapsed/refractory chronic lymphocytic leukemia.
Dr Maxwell on Real-World Germline Variant Rates in Prostate Cancer
May 23, 2024
Video
Kara N. Maxwell, MD, PhD, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer.
Dr Maxwell on the Accessibility of Genetic Testing in Metastatic Prostate Cancer
May 20, 2024
Video
Kara N. Maxwell, MD, PhD, discusses the accessibility of genetic testing in the community setting for patients with metastatic prostate cancer.
Dr Porter on the Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL
May 09, 2024
Video
David L. Porter, MD, discusses the use of CAR T-cell therapy alone or in combination regimens in relapsed/refractory chronic lymphocytic leukemia.
Insider Insights: Unveiling Takeaways from AACR 2024
April 11, 2024
Article
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.